Temsirolimus, an intravenous mTOR inhibitor has also been evaluated in a phase II trial in combination with neratinib, an oral HER2 inhibitor, in HER2 mutant advanced NSCLC patients.78 The combination therapy resulted in a 19% response rate. The gene discussed is MTOR; the disease is non-small cell lung carcinoma.